571P Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)

成纤维细胞活化蛋白 医学 体内分布 体内 体外 免疫组织化学 癌症研究 多塔 病理 癌症 内科学 生物化学 化学 生物 生物技术
作者
Dirk Zboralski,Frank Osterkamp,Andrew Simmons,Anne Bredenbeck,Anja Schumann,Matthias Paschke,Nicola Beindorff,Ajay-Mohan Mohan,Minh Nguyen,Jim Xiao,Thomas C. Harding,Aileen Hoehne,Ulrich Reineke,Christiane Smerling
出处
期刊:Annals of Oncology [Elsevier]
卷期号:31: S488-S488 被引量:12
标识
DOI:10.1016/j.annonc.2020.08.685
摘要

FAP is a membrane bound protease that has limited expression in normal adult tissues but is highly expressed on cancer associated fibroblasts (CAFs), which are abundant in most tumours. FAP-2286 is a conjugate of a FAP-binding peptide coupled to a radionuclide chelator (DOTA) for use as a potential PTRT for imaging and therapeutic applications. The potency, selectivity, and efficacy of FAP-2286 were evaluated in vitro and in vivo. Immunohistochemistry was performed using FFPE tissue specimens. FAP-2286 and its metal complexes were evaluated in in vitro biochemical and cellular assays and in vivo biodistribution, imaging, and efficacy studies. Immunohistochemistry confirmed high levels of FAP expression, predominantly in CAFs, in multiple tumour types including pancreatic, breast, and sarcoma. In contrast, FAP expression in normal tissues was limited. FAP-2286 and its metal complexes had potent affinity to human FAP protein (KD, 0.4–1.4 nM). In cellular assays, FAP-2286 showed effective binding (IC50, 1.65–3.4 nM) to FAP expressing WI-38 fibroblasts. FAP-2286 inhibited FAP protease activity (IC50, 1.6–3.2 nM), whereas limited off target activity was seen against closely related family members. In vivo biodistribution (by SPECT/CT) in mice after IV injection showed rapid uptake of 111In- and 177Lu-labelled FAP-2286 in FAP-positive tumours that was maintained for ≥120 hours, limited background in normal tissues, and a renal clearance mechanism. FAP-2286 labelled with the therapeutic β-particle emitting radionuclide 177Lu, at a specific activity of 30 MBq/nmol (low-dose group) or 60 MBq/nmol (high-dose group), had potent anti-tumour activity in FAP expressing HEK-293 xenografts after a single IV dose: tumour growth inhibition at day 14 posttreatment was 112% and 115%, respectively, with no significant weight loss. In preclinical models, FAP-2286 has a compelling profile for PTRT, including high tumour uptake and retention, and potent efficacy in FAP-positive tumours. IND-enabling nonclinical work is ongoing; clinical studies in a broad spectrum of FAP-positive cancers are planned.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
施小展完成签到,获得积分10
1秒前
大秀子完成签到 ,获得积分10
1秒前
羊羊羊完成签到 ,获得积分10
3秒前
柴胡发布了新的文献求助10
4秒前
优雅涔雨完成签到,获得积分10
4秒前
乐观小蕊完成签到 ,获得积分10
5秒前
BisonHamster完成签到,获得积分10
7秒前
JTDB发布了新的文献求助10
7秒前
哈哈完成签到 ,获得积分10
7秒前
xiaofu完成签到,获得积分10
8秒前
传奇3应助棋麟采纳,获得10
8秒前
8秒前
无辜不言完成签到,获得积分10
9秒前
zsq00完成签到,获得积分10
11秒前
12秒前
王醉山完成签到,获得积分10
14秒前
CWEI完成签到,获得积分10
15秒前
四叶草发布了新的文献求助10
15秒前
英姑应助JTDB采纳,获得10
16秒前
18秒前
qdange完成签到,获得积分10
19秒前
tcmlida完成签到,获得积分10
20秒前
柴胡完成签到,获得积分10
20秒前
雪白幻雪完成签到 ,获得积分10
22秒前
SciGPT应助科研通管家采纳,获得10
22秒前
星河长明应助科研通管家采纳,获得10
22秒前
23秒前
springkaka完成签到,获得积分10
24秒前
隐形路灯完成签到 ,获得积分10
24秒前
xixihaha完成签到,获得积分10
25秒前
阳佟半仙完成签到,获得积分10
26秒前
司空悒完成签到,获得积分10
26秒前
FP发布了新的文献求助10
26秒前
28秒前
Dannerys完成签到 ,获得积分10
29秒前
33秒前
永不止步完成签到 ,获得积分10
34秒前
苗子完成签到,获得积分10
36秒前
焱阳完成签到 ,获得积分10
37秒前
高分求助中
The three stars each : the Astrolabes and related texts 1070
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Teaching Social and Emotional Learning in Physical Education 900
Boris Pesce - Gli impiegati della Fiat dal 1955 al 1999 un percorso nella memoria 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 500
少脉山油柑叶的化学成分研究 500
Recherches Ethnographiques sue les Yao dans la Chine du Sud 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2401585
求助须知:如何正确求助?哪些是违规求助? 2101120
关于积分的说明 5297480
捐赠科研通 1828774
什么是DOI,文献DOI怎么找? 911510
版权声明 560333
科研通“疑难数据库(出版商)”最低求助积分说明 487284